1. Home
  2. ASTL vs ADCT Comparison

ASTL vs ADCT Comparison

Compare ASTL & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Algoma Steel Group Inc.

ASTL

Algoma Steel Group Inc.

HOLD

Current Price

$5.07

Market Cap

467.0M

Sector

Industrials

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$3.85

Market Cap

484.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASTL
ADCT
Founded
1902
2011
Country
Canada
Switzerland
Employees
N/A
N/A
Industry
Steel/Iron Ore
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
467.0M
484.4M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
ASTL
ADCT
Price
$5.07
$3.85
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$7.75
AVG Volume (30 Days)
1.2M
641.0K
Earning Date
05-07-2026
05-13-2026
Dividend Yield
1.00%
N/A
EPS Growth
N/A
30.86
EPS
N/A
N/A
Revenue
N/A
$81,357,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$24.62
$66.49
P/E Ratio
N/A
N/A
Revenue Growth
N/A
14.85
52 Week Low
$3.02
$1.13
52 Week High
$7.25
$4.98

Technical Indicators

Market Signals
Indicator
ASTL
ADCT
Relative Strength Index (RSI) 70.73 49.84
Support Level $4.29 $3.41
Resistance Level $5.25 $4.71
Average True Range (ATR) 0.22 0.21
MACD 0.13 0.01
Stochastic Oscillator 97.46 66.92

Price Performance

Historical Comparison
ASTL
ADCT

About ASTL Algoma Steel Group Inc.

Algoma Steel Group Inc is a fully integrated steel producer of hot and cold rolled steel products, including coiled sheet and plate, strategically located. The firm operates in a single segment of basic steel production including sheets, plates, slabs, and freights. The company's revenue is generated from contracts to produce, ship, and deliver steel products Geographically it serves Canada, the United States, and the rest of the world, whilst driving key revenue from domestic sales. The company generates the majority of its revenue from the sale of Steel sheets and strips.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: